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ABSTRACT
The actual strategy to improve current therapies in advanced prostate cancer 
involves targeting genes activated by androgen withdrawal, either to delay or prevent 
the emergence of the castration-refractory phenotype. However, these genes are 
often implicated in several physiological processes, and long-term inhibition of 
survival proteins might be accompanied with cytotoxic effects. To avoid this problem, 
an alternative therapeutic strategy relies on the identification and use of compounds 
that disrupt specific protein-protein interactions involved in androgen withdrawal. 
Specifically, the interaction of the chaperone protein Hsp27 with the initiation factor 
eIF4E leads to the protection of protein synthesis initiation process and enhances 
cell survival during cell stress induced by castration or chemotherapy. Thus, in this 
work we aimed at i) identifying the interaction site of the Hsp27/eIF4E complex and 
ii) interfere with the relevant protein/protein association mechanism involved in 
castration-resistant progression of prostate cancer. By a combination of experimental 
and modeling techniques, we proved that eIF4E interacts with the C-terminal part 
of Hsp27, preferentially when Hsp27 is phosphorylated. We also observed that the 
loss of this interaction increased cell chemo-and hormone-sensitivity. In order to find 
a potential inhibitor of Hsp27/eIF4E interaction, BRET assays in combination with 
molecular simulations identified the phenazine derivative 14 as the compound able 
to efficiently interfere with this protein/protein interaction, thereby inhibiting cell 
viability and increasing cell death in chemo- and castration-resistant prostate cancer 
models in vitro and in vivo.
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INTRODUCTION
Prostate cancer (PC) represents the second cause of 
cancer mortality in men, mainly because patients relapse 
to castration-resistant prostate cancer (CRPC) two years 
after androgen ablation. The final treatment option is 
chemotherapy (docetaxel), but the median overall survival 
is only two/three months. Recently, cabazytaxel and 
Abiraterone has been approved as chemo- and endocrine-
therapy agents but overall survival is only around 12 to 
18 months [1, 2]. The actual therapeutic strategy to delay 
or prevent the emergence of the castration-refractory 
phenotype in advanced PC involves targeting genes 
activated by androgen withdrawal (for review [3]). 
Hsp27, a heat shock protein involved in pleiotropic cell 
functions [4] (for review [5]) is a highly overexpressed 
gene in CRPC [6, 7]. Aberrant expression of Hsp27 has 
been associated with tumor growth, resistance to hormonal 
therapy, cell death inhibition, and poor prognosis [6–9]. 
Silencing of Hsp27 expression by the use of antisense 
oligonucleotides (ASOs) or small interfering RNAs 
(siRNAs) increases apoptotic rates, induces tumor 
regression and enhances hormone- and chemotherapy 
in PC [6, 7]. Despite excellent results observed in 
relevant clinical trials (http://www.oncogenex.ca/) the 
functional role of stress-induced Hsp27 in castration or 
chemotherapy-induced cell death remains poorly defined. 
The purpose of our work is to elucidate the pathways 
leading Hsp27 action in CRPC and to find new specific 
therapeutic targets and treatment strategy for CRPC that 
would have limited toxicity for normal tissues. Using two-
hybrid experiment, we previously found that Hsp27 plays 
a major role in the protein translational initiation process 
[10]. These data led us to investigate the protein synthesis 
initiation pathway, a prerequisite for cell growth and 
proliferation. Thus, by northern and western blot analysis 
we found that Hsp27 down-regulation decreased eIF4E 
expression only at the protein level, without affecting 
mRNA content. The cytoprotection afforded by Hsp27 
overexpression was attenuated by eIF4E knockdown 
using specific eIF4E siRNA. Co-immunoprecipitation 
and co-immunofluorescence experiments confirmed that 
Hsp27 co-localizes and interacts directly with eIF4E. 
Hsp27-eIF4E interaction decreases eIF4E ubiquitination 
and proteasomal degradation. By chaperoning eIF4E, 
Hsp27 protects the protein synthesis initiation process 
to enhance cell survival during cell stress induced by 
castration or chemotherapy. Forced over-expression of 
eIF4E induced resistance to androgen-withdrawal and 
docetaxel treatment in the prostate LNCaP cells line in 
vitro. In aggregate, these findings identified Hsp27 as a 
modulator of eIF4E and established a potential mechanism 
for the eIF4E-regulated cell death after androgen ablation 
and chemotherapy. Accordingly, targeting Hsp27-eIF4E 
interaction may serve as a therapeutic option in advanced 
PC [10].
In humans, a variety of tumor types have been 
previously described to exhibit elevated levels of eIF4E, 
including advanced PCs [11]. eIF4E overexpression 
and translation initiation is involved in malignant 
transformation and chemo-resistance in vitro and in vivo 
and thus represents an important target for cancer therapy 
[11]. Many approaches over the years have been used 
to try to inhibit eIF4E functions, particularly the use of 
small molecule inhibitors that can disrupt the eIF4E/eIF4G 
interaction, the use of cap analogs to directly target the 
eIF4E cap-binding site, or ASOs that have been proven 
to be efficient in reducing the expression level of eIF4E 
and are tested in many clinical trials in prostate cancer 
patients [12].
Our aim was to disrupt this mechanism involved 
in castration-resistant progression of prostate cancer. 
Towards this goal, we worked on the identification of 
the interaction site of Hsp27/eIF4E. In order to find a 
potential inhibitor of this interaction, we performed a 
screening of compounds by BRET experiments and found 
one candidate, a derivative of phenazine, compound 14, 
that was not a DNA intercaling agent and inhibited Hsp27/
eIF4E interaction leading to cell viability inhibition and 
increase of apoptosis of castration-resistant prostate cancer 
cells.
RESULTS
eIF4E interacts with the C-terminal region 
of Hsp27 leading to chemo- and hormone-
resistance and absence of Hsp27 phosphorylation 
partially inhibits this interaction
Hsp27 deletion mutants were used to determine the 
region of the heat shock protein that interacts with eIF4E 
(Figure 1a). The results showed that eIF4E interacts 
only with the Hsp27 C1 mutant, while protein/protein 
interaction was inhibited when Hsp27 was truncated in 
its C-terminal part (N1 and N2 mutants) (Figures 1b-
1c). To evaluate how the Hsp27/eIF4E interaction is 
involved in chemo-resistance, cells were transfected with 
the Hsp27 deletion mutants prior to docetaxel treatment 
in combination with androgen deprivation in rat colon 
carcinoma cancer cell line (REG) cells that have no 
endogeneous expression of Hsp27. The analysis of cells 
viability showed that cells sensitivity to chemotherapy 
(docetaxel) and androgen withdrawal (serum free media) 
increased in the presence of the N1 and N2 mutants 
(Figure 1d). Thus, our data confirmed that loss of Hsp27/
eIF4E interaction via truncation of Hsp27 C-terminal 
region restores chemo- and hormone- sensitivity in cancer 
cells.
To evaluate the effects of Hsp27 phosphorylation on 
its interaction with eIF4E Hsp27 mutants corresponding to 
constitutively unphosphorylated (3A) or phosphorylated 
(3D) forms were used (Figure 1e). The results showed that 
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Figure 1: Modeling of Hsp27 with eIF4E and phosphorylation status of Hsp27 reveal that Hsp27 C-terminal domain 
and phosphorylation are essential for protein binding and loss of this interaction increases cell chemo and hormone-
sensitivity. (a) Schematic representation of Hsp27 wild type (WT) and truncated mutant forms of Hsp27 (N1, N2, and C1). Mutants 
N1 and N2 correspond to two different variants of the N-terminal region of Hsp27 protein (residues 1-93, and 1-173, respectively), 
whereas mutant C1 corresponds to the Hsp27 C-terminal region, containing the last 113 protein residues (residues 93-205). The full-
length WT Hsp27 sequence was used as control. No endogenous Hsp27 expression REG cells transiently transfected or not (NT) with 
plasmids containing WT Hsp27 and N1, N2 and C1 and proteins were extracted for: (b) Western Blot analysis of histidine and vinculin 
protein levels from total cell lysates (TCL) and (c) Western Blot analysis of histidine and eIF4E protein levels after immunoprecipitation 
(IP) using anti-eIF4E antibody (d) MTT quantification of REG cells viability. (e) Schematic representation of Hsp27 wild type (WT) 
and phosphorylation mutants of Hsp27 (3A and 3D) used in this study. In the former case, the 3A mutant of Hsp27 was specifically 
constructed by replacing the serine residues 15, 78 and 82 with alanine; concomitantly, the 3D Hsp27 isoforms was obtained by replacing 
the same serine residues with aspartic acid. (f) Western Blot analysis of histidine and vinculin protein levels from total cell lysates 
(TCL) and (g) Western Blot analysis of histidine and eIF4E protein levels after immunoprecipitation (IP) using anti-eIF4E antibody. 
(h) MTT quantification of REG cells viability was performed on cells transiently transfected with plasmids containing WT Hsp27 and 
phosphorylation mutants of Hsp27 prior to treatment with docetaxel in serum-free media (a condition mimicking androgen deprivation) 
*** P≤0.001. (i) Overall view of an equilibrated MD snapshot of the Hsp27 WT/eIF4E complex. The proteins are visualized by their 
van der Waals surfaces, colored as follow: Hsp27 WT, firebrick; eIF4E, khaki. The amino acids of Hsp27 mainly involved in binding 
eIF4E are highlighted as follows: purple, residues belonging to the WDPF domain; green, residues belonging to the flexible domain. 
See text for details. (j) Per residue enthalpic contribution to WT Hsp27 binding with eIF4E. Only those Hsp27 amino acids affording a 
meaningful contribution to protein-protein formation contributing (ΔHbind,res < -0.80 kcal/mol) are shown for clarity. From this analysis, 
it further appears that the Hsp27 α-crystallin domain is practically ineffective in Hsp27/eIF4E binding since residues belonging to this 
Hsp27 region display a negligible contribution to protein-protein binding enthalpy. (k) Overall view of equilibrated MD snapshots of the 
eIF4E in complex with Hsp27 N1, N2 and C1 truncated mutant isoforms. In each panel, the proteins are visualized by their van der Waals 
surfaces, colored as follows: Hsp27s, firebrick; eIF4E, khaki. The amino acids of Hsp27 mainly involved in binding eIF4E are highlighted 
as follows: purple, residues belonging to the WDPF domain; green, residues belonging to the flexible domain. Interestingly, the overall 
structure of Hsp27 N1 is de facto strongly affected by the loss of the α-crystallin domain, which plays a major role in the overall correct 
chaperon folding required for effective binding to eIF4E.
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the interaction of eIF4E with the phosphorylated form of 
Hsp27 (3D mutant) was similar to the one observed with 
the WT protein, while partial inhibition of the interaction 
was found with the unphosphorylated form (3A mutant) 
(Figure 1f–1g) showing that phosphorylation regulates 
the interaction. To understand the implication of Hsp27 
phosphorylation on cell drug resistance, transfected cells 
were treated with docetaxel in serum free media. The 
analysis of cell viability showed that the unphosphorylated 
3A mutant of Hsp27 restored sensitivity to cell death 
driven by docetaxel and androgen withdrawal, while no 
effect on cell viability was observed in the case of the 
constitutively phosphorylated mutant mimics (3D) (Figure 
1h). The same results have been obtained in LNCaP 
prostate cancer models (data not shown). These results 
demonstrate that Hsp27 phosphorylation partly regulates 
Hsp27/eIF4E interaction and confirm that loss of this 
interaction can induce treatment-sensitivity.
To rationalize these results at a molecular level, 
first extensive molecular dynamics (MD) run was carried 
out on the WT Hsp27/eIF4E complex (Figure 1i). The 
retrieved inter-protein binding free energy ΔGbind value of 
-11.86 kcal/mol (Table 1) revealed a good affinity between 
the two polypeptides, in agreement with the experimental 
evidences. A per-residue binding enthalpy (ΔHbind,res) 
analysis [13, 14] allowed to determine which Hsp27 
residues are mainly involved in this interaction (Figure 1j). 
Accordingly, we found that WT Hsp27 binds the initiation 
factor mainly by exploiting the initial residues of the 
domain WDPF (W=tryptophan, D=aspartic acid, P=prolin 
and F=phenylalanine) and the final residues of the flexible 
domain in the C-terminal region, these last providing a 
favorable contribution to the binding two times larger than 
that afforded by the amino acids of the N-terminal part 
(Figure 1k).
The same computational approach was applied to 
the binding of the three truncated forms of Hsp27 (i.e., 
N1, N2, and C1) to the eIF4E protein. As expected, the 
ΔGbind values of the truncated forms were all less favorable 
compared to the WT protein (Table 1). Yet, a specific 
trend could be clearly discerned. Indeed, the presence 
of the C-terminal part still endow the Hsp27 C1 mutant 
with good eIF4E binding capability, inducing only a 
small decrease in binding affinity with respect to the WT 
(ΔGbind(C1) = -9.99 kcal/mol). On the other hand, the Hsp27 
N2 isoform is still able to maintain a minimal affinity 
against the eIF4E through its WDPF residues; however, 
the absence of the C-terminal region leads to a strong 
reduction of the interaction surface (Figure 1h) and this, 
in turn, reflects into a loss of almost 6 kcal/mol in ΔGbind 
(Table 1). Lastly, the presence of the sole WDPF domain 
in the N1 Hsp27 mutant form allows the formation of a 
network of very weak interactions with eIF4E, reflecting 
in a plummet of ~9 kcal/mol in the relevant value of ΔGbind 
(Table 1, Figure 1i). In aggregate, our in silico results 
confirmed that the most important interactions involved 
in binding of the Hsp27 protein with the initiation factor 
eIF4E are provided by its C-terminal part, strictly in 
agreement with the co-immunoprecipitation experiments.
Screening of chemical compounds using BRET 
assay identify that phenazine#14 disrupt Hsp27/
eIF4 interaction
To further visualize Hsp27/eIF4E interaction and in 
search for eventual inhibitors of this interaction, BRET 
assay in living cells and in cell extracts were performed 
using different combination of constructs (Figure 2a) 
of Hsp27 and eIF4E with YFP (Yellow Fluorescent 
Protein) or luc (luciferase) bound either to the N- or to the 
C-terminal region of both proteins (see SI). We confirmed 
the interaction between fusion protein Hsp27/YFPC-
ter and fusion protein N-terluc/eIF4E in HEK293T living 
cells (Figure 2b). BRET signal with the same couple of 
proteins was obtained as previously described for BRET 
experiment on living cells (Figure 2c). Next, to identify 
potential inhibitors of the Hsp27/eIF4E interaction, a 
screening of chemical compounds on cell extracts was 
carried out. We performed our screening using phenazine 
derivatives that were previously shown to have an anti-
tumor activity in pancreatic and prostatic cell lines [15, 
16] and structure similar to inhibitors of the eIF4E/eIF4G 
interaction (Figure 2d). At the same time, we tested 
the compound “4E2RCat” reported in literature as an 
inhibitor of the eIF4E/eIF4G interaction, in order to see 
if it also inhibited the Hsp27/eIF4E interaction [17, 18] 
(Figure 2e). Of all compounds tested, only 14 revealed 
a dose-dependent inhibitory effect on the Hsp27/eIF4E 
interaction (Figure 2f). Other phenazine derivatives, as 
well as 4E2RCat, showed no significant inhibition (not 
Table 1: Binding free energies (ΔGbind) and binding free energy differences (ΔΔGbind) for the Hsp27 WT, N1, N2 and 
C2 truncated mutants in complex with eIF4E. (ΔΔGbind=ΔGbind(WT)- ΔGbind(truncated))
Complex ΔGbind(kcal/mol) ΔΔGbind(kcal/mol)
Hsp27 WT -11.86 ± 0.24 -
Hsp27 N1 -3.06 ± 0.27 -8.80
Hsp27 N2 -6.05 ± 0.23 -5.81
Hsp27 C1 -9.99 ± 0.25 -1.87
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Figure 2: Validation of Hsp27/eIF4E interaction by BRET in whole living cells and in cells extracts and revelation of 
the chemical compound 14 as a specific inhibitor Hsp27/eIF4E by BRET screening. (a) To by-pass technical parameters 
that could prevent us from measuring a BRET signal (presence and/or position of the reporter proteins that could disrupt the Hsp27/eIF4E 
interaction, physical distance between Rluc and YFP), the interaction between these two proteins with all possible couple combinations 
(n=8) of plasmids were tested. These couples of plasmids were transfected separately in HEK293T cells at different concentrations in 
order to find the ideal ratios and obtain the BRET signal. For the construction of BRET plasmids, we merged each gene (Hsp27 and 
eIF4E) with Rluc or YFP in N-terminal (N-ter) or C-terminal (C-ter) part. After, we tested the interaction between these two proteins 
with all the possible couple combinations of plasmids, on BRET on living cells or cells extracts. (b) Hsp27/eIF4E interaction in BRET 
experiment was investigated in HEK293T cell extracts. The principle was similar to BRET assay in living cells; except that the plasmids 
were transfected separately in HEK293T cells and that the couple combinations were tested in vitro by mixing proteins extracted from 
these transfected cells. HEK293T cells were co-transfected with 0.2 μg of BRET donor plasmid N-terluc/eIF4E, and 0 to 1 μg of BRET 
acceptor plasmid Hsp27/YFPC-ter. The empty vector (pEYFP-C) was used to equalize DNA amounts to 1.2 μg in each sample. The 
reading of optic density was performed after the addition of coelenterazine in order to obtain the BRET signal. (c) HEK293T cells 
were transfected separately with a BRET donor plasmid N-terluc/eIF4E or BRET acceptor plasmid Hsp27/YFPC-ter. Δ=(YFP/Luc-YFP0/
Luc0)*1000. (d) Derivatives of phenazines that have been described to have an anti-tumor activity as well as a structure similar to 
inhibitors of eIF4E/eIF4G interaction. (e) Compound 4E2RCat, which is described in literature to be an inhibitor of the eIF4E/eIF4G 
interaction. (f) HEK293T cells were transfected separately with a BRET donor plasmid N-terluc/eIF4E or BRET acceptor plasmid Hsp27/
YFPC-ter. Total proteins were extracted from cells and used for BRET assay: 1 μg of lysate containing a BRET donor and 0 to 15 μg of 
lysate containing a BRET acceptor were pre-incubated separately with different concentrations (0, 20, 50 and 100μM; green, yellow, 
orange and red lines respectively) of compound 14 during 2h. As control experiment, cell extracts were pre-incubated with DMSO alone, 
at the higher concentration (1%) we used to dilute compound (control DMSO, blue line). Donor and acceptor were mixed for 30 min 
and the reading of optic density was performed after the addition of coelenterazine in order to obtain the BRET signal. (g) The same 
experiment was performed with another couple of protein: CCND3/luc and CDK6/YFP (4μg of lysate containing BRET donor was 
used). Δ=(YFP/Luc-YFP0/Luc0)*1000. (h) PC-3 cells were treated at 100μM with compound 14 (right panel, Bar=10 μm) and DMSO 
(left panel, Bar = 20μm) as control. Auto-fluorescence of compound 14 (green) and staining of the nucleus by DAPI (blue) was observed. 
PC-3 cells were treated with DMSO (control) or compound 14 during 48h and proteins were extracted for: (i) Western Blot analysis of 
Hsp27, eIF4E protein levels after immunoprecipitation (IP) using eIF4E rabbit antibody or IgG rabbit (control) (j) Western Blot analysis 
of Hsp27, eIF4E, Vinculin and protein levels from total protein extracts.
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shown). To see if this inhibition was specifically due 
to Hsp27/eIF4E interaction rather than to non-specific 
protein degradations, 14 was tested on an irrelevant couple 
of proteins, CCND3/Luc and CDK6/YFP. The result 
showed no inhibition of this interaction by 14, supporting 
the specificity of Hsp27/eIF4E interaction inhibition 
(Figure 2g). This screening allowed us to highlight 14 as 
the first compound that potentially inhibits Hsp27/eIF4E 
interaction.
To confirm the fact that the phenazine-derivative 
14 can inhibit the Hsp27/eIF4E endogeneous interaction 
in cells, we performed immunofluorescence and co-
immunoprecipitation experiments. Our results performed 
in androgen-independent prostate cancer PC-3 cells 
demonstrated that 14 is located in the cell cytoplasm 
(Figure 2h) prevents the Hsp27-eIF4E interaction (Figure 
2i) without any effect on proteins expression levels (Figure 
2j).
Computational studies confirm the inhibition 
of Hsp27/eIF4E interaction by the phenazine 
14 and reveal the potential the molecular 
mechanism of the inhibition
The BRET assay established that compound 14 
inhibits the interaction between the WT Hsp27 protein 
and the initiation factor eIF4E. We reasoned that this 
disruption could be caused by the binding between the 
initiation factor and 14, with the subsequent alteration 
of the protein structure. The final effect could ultimately 
translate in the modification of the interaction surface 
between eIF4E and WT Hsp27, which, in turn, implies 
impairing the corresponding energy of binding. To verify 
this hypothesis, a plausible binding cavity for 14 in a 
region of the protein that belongs to the interacting surface 
of the Hsp27/eIF4E complex was identified (Figure 3a). 
Then, (MD) simulation of the resulting eIF4E/14 complex 
was carried out, and the MM/PBSA results yielded a good 
binding affinity of the molecule for the protein (ΔGbind = 
-9.05 kcal/mol), in agreement with its inhibitor activity 
demonstrated in the BRET assay.
The specific eIF4E/14 binding mode was again 
analyzed by a per-residue decomposition of the enthalpic 
component of the free energy of binding ΔHbind,res*. The 
collected data (Figure 3a) revealed that the eIF4E/14 
complex is stabilized by three main interaction types: i) a 
network of stabilizing hydrophobic interaction involving 
the two C12 alkyl chains of the 14; ii) two persistent polar 
interaction anchoring both amine substituents of 14 to 
the protein, and iii) a weak hydrogen bond engaging a 
nitrogen atom of the phenazine ring (Figure 3a).
The stable complex between 14 and eIF4E had 
also an important consequence from the protein structure 
viewpoint, in that it reflects in an overall arrangement of 
the eIF4E structure, specifically in the region involved 
in the protein-protein interface with Hsp27 (Figure 3b). 
To corroborate this assumption, the same computational 
approach was applied to the WT Hsp27/14/eIF4E 
complex, and the inhibitory effect of 14 was quantified. 
Actually, the presence of the ligand leads to a drastic 
reduction of the binding interactions between WT Hsp27 
and the initiator factor, with a loss of about 5.5 kcal/mol 
in the corresponding calculated free energy of binding 
(Figure 3c).
Titration of 14 into the protein solution by Isothermal 
Titration Calorimetry (ITC) confirmed the binding results 
obtained by our computational procedure (Figure 3d). 
Indeed, the affinity of 14 for eIF4E is in the nanomolar 
range (KD=175 nM). Moreover, the corresponding ΔG 
values of -9.22 kcal/mol (obtained from the fundamental 
relationship ΔG = RT lnKD), is in outstanding agreement 
calculated by MM/PBSA computational approach (-9.05 
kcal/mol, see above). For the thermodynamic viewpoint, 
the process is largely enthalpy driven (ΔH = -10.3 kcal/
mol), while entropy variation slightly disfavors binding 
(-TΔS=1.06 kcal/mol). Finally, the molar ratio identified 
from the number of ligands per protein (n) is very close to 
1 (n = 0.974), definitely supporting a 1:1 stoichiometry for 
the 14/eIF4E complex.
Hsp27/eIF4E inhibition by phenazine 14 restores 
treatment sensitivity of androgen-independent 
prostate cancer models in vitro and in vivo
In order to evaluate the effect of the Hsp27/
eIF4E interaction inhibition in prostate cancer model, 
we treated androgen-independent (PC-3) and docetaxel-
resistant (PC3-DR) cells with different concentrations 
of phenazine 14. The inhibition of Hsp27-eIF4E 
interaction by 14 decreased cells viability in a dose-
dependent manner (Figure 4a) and increased cell death 
in androgen-independent PC-3 model (Figure 4b). More 
interestingly, derivative 14 restored chemo-sensitivity in 
docetaxel-resistant induced PC-3DR cells [19] (Figure 4c). 
Encouraged by the nontoxic, promising in vitro results 
obtained with compound 14, in vivo experiments were 
conducted to assess its effect on tumor growth. Figure 4d 
shows that 14 (green line) significantly reduced androgen-
independent PC-3 tumor growth (***P ≤ 0.01) by up to 
50% compared to PBS treatment (blue line). AT killing, 
tumor volume from animals treated with compound 14 
were smaller than those harvested from PBS treated group 
(Figure 4e).
Immunohistochemical study analysis (Figure 4f) 
demonstrated that the proliferation index level (Ki-67) 
of compound 14 treated groups was significantly lower 
than that of control group (PBS), indicating lower cell 
proliferation in tumors and hence higher antitumor activity 
of this molecule. Optical density (OD) that correlates with 
the antigen expression was next measured. We found that 
the mean of Ki67 expression was significantly increased 
in tumors treated with PBS compared with tumors treated 
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Figure 3: Molecular modeling and isothermal titration calorimetry (ITC) reveal the mechanism of Hsp27/eIF4E 
interaction inhibition by compound 14. (a) (Left panel) Zoomed view of an MD equilibrated snapshot of the 14 in complex with 
eIF4E. Specifically, the ligand is docked between a α-helix of eIF4E protein spanning residue L117*-E132* and a structurally hybrid 
region from E185* to I193*. The ligand is portrayed in ball-and-stick representation and colored by element (C, gray; N, blue; O, 
red). The main protein residues involved in compound binding are depicted as gold sticks and labelled. Transparent light blue spheres 
represent water oxygen atoms, while chlorine and sodium ions and counterions are shown as green and purple spheres, respectively. 
Hydrogen atoms are omitted for clarity. (Right Panel) Per residue binding enthalpy decomposition for eIF4E residues mainly involved 
in binding with 14. Only those Hsp27 amino acids affording a meaningful contribution to protein-drug formation (ΔHbind,res* < -0.50 
kcal/mol) are shown for clarity. The network of stabilizing hydrophobic interaction involves the two C12 alkyl chains of the 14 and 
the side chain of the protein residue L117*, N118*, F129*, L189*, P190*, K192*, and I193*. The two amine substituents of 14 are 
engaged in two persistent polar interactions with the carboxylic side chain of E132* and E185*. In addition, a further stabilizing 
interaction via a weak hydrogen bond between the side chain of R128* and a nitrogen atom of the phenazine ring is detected. (b) (Left 
panel) MD simulation distance between the charged side chains of E132* and R186* in the eIF4E alone (red line) and in the eIF4E/14 
complex (salmon line). In the eIF4E free protein, the two α-helixes spanning residues Q122*-I138* and R173*-G188*, respectively, are 
persistently stabilized by the presence of permanent interaction points between the side chain of their residues. In particular, a strong 
polar interaction between the charged side chain of the amino acids E132* and R186* is detected. As shown, the Average Dynamics 
Length (ADL) of this interaction between the two involved atoms is 2.96 Å, and its persistence is verified along the entire MD run. 
Conversely, the same distance progressively increases during the first part of the simulations and finally settles around 9Å when the 
eIF4F is simulated in presence of the ligand. The reason for this behavior can be explained by that fact that E132* is engaged in a 
polar interaction with 14, as demonstrated by the complementary trend exhibited of the corresponding distance between the carboxylic 
moiety of E132* and the amine group of 14 shown in the right panel (MD simulation distance between the N2 nitrogen atom of 14 and 
the charged side chain of E132* (blue line), and between the N3 nitrogen atom of 14 and the charged side chain of E185* (green line). 
(c) (Left panel) Overall view of an equilibrated MD snapshot of the Hsp27 WT/eIF4E/14 complex. All molecules are visualized by 
their van der Waals surfaces, colored as follow: WT Hsp27, firebrick; eIF4E, khaki; 14, navy blue. The amino acids of Hsp27 mainly 
involved in binding eIF4E are highlighted as follows: purple, residues belonging to the WDPF domain; green, residues belonging 
to the flexible domain. The residues of eIF4E mainly involved in binding with 14 are depicted in gold. (Upper right panel) Binding 
free energies (ΔGbind) and binding free energy differences (ΔGbind) for the WT Hsp27/eIF4E (plain filled columns) and the WT Hsp27/
eIF4E/14 (patterned filled columns) complexes. (Lower right panel) Comparison of the clustered per residue enthalpic contribution to 
binding for WT Hsp27/eIF4E and WT Hsp27/eIF4E/14 complexes. (d) ITC experiment of 14/eIF4E binding: (left) raw data; (middle) 
titration curve; (right) binding thermodynamics parameters.
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with 14 (26.09 ± 0.17 and 13.7 ± 0.18, p < 0.0001) (Figure 
4g). These results confirmed the efficacy of the phenazine-
derivative 14 in decreasing tumor proliferationinandrogen-
independent PC-3 models.
DISCUSSION
Development of CRPC is an inevitable 
progression of PCs after androgen ablation. At this 
stage, treatment options are very limited. Until recently, 
the chemotherapeutic agent docetaxel represented the 
treatment of choice after castration resistance emerged, 
prolonging the mean life span of patients for 2.9 months 
[20]. Overexpression of anti-apoptotic proteins, mRNA 
splicing events, gene fusions, loss of expression of tumor 
suppressor genes, post-transcriptional modification using 
miRNA, and epigenetic alterations are all hallmarks 
of CRPC [3]. Hsp27 has numerous cytoprotective 
functions and is involved in cell migration, cytoskeleton 
architecture, cell growth, differentiation, and tumor 
Figure 4: Compound 14 inhibits cell viability and increases apoptosis in vitro and in vivo. Cells viability using MTT assay 
(a) was performed on PC-3 non treated (NT) or treated cells with compound 14 (a) at different concentrations (25, 50, 100μM) during 48h. 
Cell death quantification (SubG0 phase) using flow cytometry (b) was performed on PC-3 cells non treated (NT) or treated with compound 
14 at 100μM during 48h. Cell viability using MTT assay was also performed on PC-3-docetaxel resistant cells non treated (NT) or treated 
with compound 14 (c) at different concentrations (25, 50, 100μM) during 48h. (d) PC-3 cells were subcutaneously implanted in Node Scids 
by injection of 10 ×10 6 cells in the right flank of animals. When tumors reached 100mm3, mice were randomized in two groups that received 
twice a week an intra-peritoneal injection of PBS (control n = 6, blue) and phenazine 14 (n = 8, green) (1 mg/kg) for 8 weeks. Tumor volume 
was measured once weekly and calculated by the formula length x width x depth x 0.5236. Compound 14 reduced significantly PC-3 tumor 
volume by up to 50%. During the entire treatment period, all mice treated with PBS and 14 did not show any abnormal behavior, and no 
significant alteration of mice body weight was observed. (e) Photographs of PC-3 harvested tumors from mice that received i.p. compound 
14 or control-PBS after an 8-week treatment (f) Ki-67 IHC staining of tumor tissues to assess tumor cells proliferation. (g) Distribution of 
tissue Ki-67 immunostaining intensity (measured as average optical density) according to the tumor treated with PBS and Compoud#14. 
Error bars represent the SE, **, P ≤0.01 and ***, P ≤ 0.001 by Statview software.
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progression [21]. Despite the promising clinical trial 
results of Hsp27 inhibitor (OGX427, Apatorsen), long-
term inhibition of the survival protein Hsp27 might be 
accompanied by cytotoxic effects due to the role of this 
protein in several physiological processes [22]. To avoid 
this problem, an alternative therapeutic strategy consists 
of using compounds that disrupt specific protein-protein 
interactions (PPIs) between Hsp27 and partners that 
mediate its cytoprotective effects [10, 21, 23].
In our previous investigations, we showed 
that Hsp27 interacts directly with eIF4E. Hsp27/
eIF4E interaction decreases eIF4E ubiquitination and 
proteasomal degradation. By chaperoning eIF4E, Hsp27 
appears to protect the protein synthesis initiation process 
to enhance cell survival during cell stress induced 
by castration or chemotherapy [10]. In this study, we 
sought to further characterize important facets of the 
interaction between Hsp27 and eIF4E. First, using both 
co-immunoprecipitation (Figure 1) and BRET assays 
(Figure 2), we demonstrated that the interaction between 
Hsp27 and eIF4E may involve the C-terminal domain of 
Hsp27, and that loss of this interaction restores chemo- 
and hormone-sensitivity of PC. Next, we determined 
that phosphorylation of Hsp27 enhances its interaction 
with eIF4E (Figure 1f–1g). Finally, we identified and 
characterized the first compound, 14 able to inhibit the 
Hsp27/eIF4E interaction (Figure 3).
To evaluate the effects of Hsp27 phosphorylation 
on its interaction with eIF4E, we used phosphorylated 
(3D) and non-phosphorylated (3A) forms to Hsp27. By 
immunoprecipitation we showed that eIF4E interacts with 
the phosphorylated forms of Hsp27, while only a partial 
interaction inhibition with the non-phosphorylated form 
of Hsp27 (Figure 1g) was detected. Structure and function 
studies indicate that the chaperone properties of Hsp27 
correlate with the ability of the protein to form large 
oligomers, which are mediated by the non-phosphorylated 
form of Hsp27 [24, 25]. On the other hand, the triple 
mutant phosphorylated (3D) mimic is capable of forming 
at most tetramers and has less chaperone activity than the 
wild type protein [26].
Zoubeidi et al. have shown that phosphorylated 
Hsp27 displaces Hsp90 from androgen receptor thus 
taking its place, which allows transport of the receptor in 
the nucleus with subsequent activation and transcription 
of target genes. This interaction further avoids MDM2/
AR binding and promotes MDM2 ubiquitination and 
degradation by the proteasome [27]. Our work indicates 
that Hsp27 has a similar role on eIF4E, protecting it from 
degradation by the ubiquitin/proteasome system and 
allowing maintenance of protein synthesis. The hypothesis 
of the "sorting" function of this protein is reinforced by 
the fact that Hsp27 seems to be selective with respect to 
targets to be degraded. For example, it acts on p27 kip1 but 
has no action on other cell cycle proteins such as cyclin A, 
E, D1 or β-catenin [28, 29].
Another observation drawn from this study is that 
when only the N-terminal domain of Hsp27 is expressed 
it does not seem to interact strongly with eIF4E. The C-ter 
part of Hsp27 (C1 mutant) and the loss of this interaction 
(N1 and N2 mutants) are both involved, at least in part, in 
the increase of treatment-sensitivity of the cells (Figure 
1b–1c). Thus, different portions of the Hsp27 molecule 
may be responsible for mediating the response to different 
stimuli. For example, the C-terminal domain may be 
largely responsible for the response to stress, whereas the 
N-terminal could be responsible for modulating hormonal 
signaling [30]. Another study indicates that the C-terminal 
of Hsp27 retains its flexibility during the interaction with 
dithiothereitol and suggests a highly flexible C-terminal in 
mammalian sHSPs is required for full chaperone activity 
[31].
It has been shown that the C-terminal 
phosphorylation of Hsp70 and Hsp90 acts as a switch for 
regulating co-chaperone binding and indicates that cancer 
cells possess an elevated protein folding environment 
by the concerted action of co-chaperone expression and 
chaperone modifications [32]. Literature data indicate that 
the chaperone-like activity of small heat shock proteins is 
dependent on the properties of the C-terminal extension 
and deletion [31, 33].
The overexpression of Hsp27 in cancer tissues is 
correlated with anti-cancer drug resistance, which makes 
Hsp27 a promising molecular target for drug development 
[8, 10]. Our present results demonstrate that compound 14 
has a dose-dependent inhibitory effect on the Hsp27/eIF4E 
interaction (Figure 2f) in a BRET assay. Accordingly, 14 
could represent an efficient and selective new anticancer 
compound, so far being the only phenazine derivative able 
of inhibiting the Hsp27/eIF4E interaction.
BRET assay constitutes an efficient methodology to 
study PPIs under native conditions compared with other 
screening assays performed using soluble fragments of 
the target protein. Our actual BRET assay demonstrated 
the capacity of compound 14 to disrupt Hsp27/eIF4E 
interaction. By analogy, the BRET approach was 
previously used with success in order to design and 
synthetize inhibitors able to disrupt Mcl/Bim interaction 
in ovarian carcinomas [34]. These inhibitors have the 
ability to dissociate Mcl-1 from Bim in whole living cells 
and acquired sensitivity ovarian cancer cells to Bcl-X and 
increased cell death.
Recently, other phenazine derivatives (2, 
3-dialkoxyphenazines, e.g., compound 11) were classified 
as anticancer agents. Indeed, these compounds were tested 
in vitro on human pancreatic cells lines (MiaPaCa-2) 
proving that these compounds appeare to be more 
cytotoxic than gemcitabine. In vivo results demonstrated 
an activity comparable to standard drug but at 10 times 
lower concentration [15].
As shown in Figure 4d, administration of free 
compound 14 moderately retarded tumor growth at 
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1mg/kg dosage, which was further supported by the 
immunohistochemical (IHC) analysis and quantification to 
evaluate tumor cell proliferation. Figure 4f reveals that the 
Ki-67 level of compound 14 treatment group was much 
lower than those of the alternative treatment group (PBS), 
indicating lower cell proliferation in tumors and hence 
higher antitumor activity of 14. In this study, we managed 
to determine the site interaction between two proteins 
considered as therapeutic targets in PC. Indeed, eIF4E is 
considered to be a proto-oncogene and its overexpression 
causes tumorigenic transformation of fibroblasts [35], 
while the overexpression of Hsp27 causes the resistance 
of tumor cells to treatment. The rationale of targeting 
Hsp27/eIF4E interaction is that long-term inhibition of 
two proteins separately may be toxic for the cells. Indeed, 
Hsp27 is a multifunctional protein involved in several 
biological processes and long inhibition of eIF4E leads to 
deregulation and malfunction of the translation initiation 
mechanism disrupting the process of cell transformation.
This work also allowed to better characterize the 
Hsp27/eIF4E interaction and demonstrated specific 
inhibition of this interaction by the phenazine-derivative 
14. Indeed, the treatment of cells with 14 inhibited 
proliferation of androgen-independent cells in vitro and 
in vivo and restored docetaxel sensitivity in docetaxel-
resistant PC cell. In conclusion, the phenazine-derivative 
14 could represent an interesting therapeutic option to 
restore hormone- and chemo-sensitivity in late stage 
of the disease where there is no therapeutic alternative. 
We are currently working to improve solubility and 
biodisponibilty of this phenazine 14 compound by using 
nucleolipids nanovectors in order to be tested in further 
clinical trials.
MATERIALS AND METHODS
Cell lines and cell culture conditions
The human androgen-independent cell line 
PC-3 (American Type Culture Collection, USA) were 
maintained in DMEM (PC-3) media (Invitrogen, France) 
supplemented with 10% fetal bovine serum (FBS). The 
rat colon carcinoma cancer cell line REG was provided 
by Dr Carmen Garrido (INSERM U866, Dijon, France) 
and maintained in F10 medium (Invitrogen) supplemented 
with 10% FBS. The Human Embryonic Kidney cell line 
HEK293T (American Type Culture Collection, USA) 
was maintained in Dulbecco’s Modified Eagle’s Medium 
(Invitrogen), supplemented with 10% FBS. All cell lines 
were cultivated at 37°C in 5% CO2. PC-3DR-docetaxel 
resistant cell line [19] was kindly provided by Dr Martin 
Gleave (Vancouver Prostate Cancer Center) and was 
maintained in culture as previously described.
Transient transfections of cells
Cells were transfected with the FuGENE HD 
Transfection Reagent (Promega, France) the day after 
seeding with 10μg DNA Hsp27 deletion mutant or Hsp27 
phosphorylation mutant plasmids (see Hsp27 mutant 
plasmids) or BRET plasmids (see BRET section), as 
previously described [36].
Immunoprecipitation
Cleared lysates with adjusted protein concentration 
(Pierce BCA Protein assay, Thermo Fisher scientific, 
France) were used for immunoprecipitation with 8 μl 
(1/50) of rabbit anti-eIF4E antibody (Cell Signaling, 
Ozyme, France) ON at 4°C as previously published 
[36]. Precisely, immune complexes were precipitated 
after 1 hour incubation with 30 μl of TrueBlot anti-rabbit 
Immunoglobulin beads (eBiosciences, Paris, France). The 
complexes were resuspended in protein sample buffer 
(Bio-Rad) and boiled for 5 minutes before western blot 
as described before. We used the rabbit TrueBlot anti-
rabbit IgG secondary antibody (eBiosciences) to reveal 
the western blot.
Western blot
Western blot (WB) was performed with 1/3000 
mouse anti-polyHistidine antibody (Sigma-Aldrich, 
USA), 1/1000 rabbit anti-eIF4E antibody (Cell Signaling, 
Ozyme), 1/2500 anti-mouse IgG HRP conjugate antibody 
(Promega, France), 1/1000 anti-rabbit Trueblot IgG HRP 
conjugate antibody and 1/1000 anti-mouse Trueblot IgG 
HRP conjugate antibody (eBiosciences), 1/5000 anti-rabbit 
IgG HRP conjugate antibody (Santa Cruz Biotechnology, 
Germany), 1/5000 rabbit Hsp27 antibody (Assay Designs, 
FranceLoading levels were normalized using 1/2000 
mouse anti-vinculin antibody (Sigma-Aldrich). Re-blot 
Plus Mild Solution (Millipore, France) was used for 
membrane stripping during 9 min at RT.
In vitro cell viability assay
Cells were transiently transfected the day after 
seeding with Hsp27 deletion or phosphorylation 
mutant plasmids as described above, or treated with 
14. Transfected cells were then treated with docetaxel 
(Sanofi-Aventis, France) in serum-free media (mimicking 
androgen withdrawal in vitro) for 24h. Cell viability was 
assessed using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide (MTT) assay for REG, PC-3 and PC-
3RD cells, as previously described [36]. Each assay was 
performed in triplicate.
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Statistical analysis for viability assays
Statistical analysis was performed using the 
GraphPad Prism program (GraphPad Software, San 
Diego, USA). All data are mean ± SEM. Significance of 
differences was assessed by a two-tailed Student's t-test. 
*P ≤ 0.05 was considered significant, with **P ≤ 0.01 and 
***P ≤ 0.001.
Confocal microscopy
PC-3 cells were seeded into a 12-well plate 
containing cover glasses treated with FBS, at a density 
of 100 000 cells/well. 24h later, cells were treated with 
compounds (14, DMSO) at 100μM as indicated above. 
After 48h of treatment, cells were washed with PBS1X 
and fixed with formaldehyde 4% (Thermo Fisher 
Scientific, France) during 15’ at RT. Further extensive 
washing was performed with PBS1X before mounting 
the cover glasses on glass slides by using Prolong Gold 
anti-fade reagent with DAPI (Life Technologies, France). 
Glass slides were allowed to dry in the dark at RT for 
24h, and cover glasses were then immobilized with nail 
polish. Fluorescent images of compound 14 (absorption; 
452nm, emission; 478nm) and DAPI (absorption; 350nm, 
emission; 450-490nm) were captured with a Zeiss 510 
META fluorescence confocal microscope plan 40X/1.4 
(Le Pecq, France).
Flow cytometry
Flow cytometry of propidium iodide-stained nuclei 
was performed as described previously [36]. Briefly, 
PC-3 cells were seeded into 10-cm dishes at a density 
of 125 0000 cells/well. 24h later, cells were treated with 
compounds 14 at 100μM as indicated above. DNA content 
was determined by flow cytometry using a LSRII SORP 
(Becton Dickinson, France) machine. Rates of cells death 
were then measured using FlowJo software (Tree Star, 
Inc.).
Assessment of in vivo tumor growth
106 PC3 cells were inoculated in the flank region 
of 2-week-old athymic male mice (NSG). Tumors were 
measured weekly and their volume was calculated 
by the formula length×width×depth×0.5236. When 
tumors reached 100 mm3, mice were randomly selected 
for treatment with PBS (control) or 14 alone. Each 
experimental group consisted of 6 control mice and 8 
mice treated with 14. Phenazine 14 was tested at its 
highest solubility (1mg/ml). Injection lasted 8 weeks with 
two injections per week. Data points were expressed as 
average tumor volume levels ±SE.
Immunohistochemistry
3 μm paraffin sections of tumors were dried 
overnight at room temperature. Before antibody staining, 
the slides were first incubated for 1.5 h at 65 °C, then 
incubated for 20 min at 95 °C with EnVision FLEX Target 
Retrieval Solution (low pH, pH 6) (K8005; Dako UK Ltd.), 
followed by pretreating with Epitope Retrieval Solution 
(containing detergent; K5207; Dako UK Ltd) for 30 min 
at room temperature to unmask binding epitopes. After 
blocking of endogenous peroxidase activity with Dako 
EnVision FLEX Peroxidase- Blocking Reagent SM801 
(ready to use) (K8000, K8002, K8023; Dako UK Ltd.) for 
5 min, the slides were washed thoroughly in wash buffer 
FLEX (Dako UK Ltd). After one wash in FLEX buffer, the 
slides were incubated with a FLEX Monoclonal Mouse 
Anti-Human Ki-67 (clone MIB-1, IR62; Dako UK Ltd.) 
for 1 h at room temperature. After two more washes in 
FLEX buffer, Dako EnVision FLEX/HRP SM802 (K8000; 
Dako UK Ltd.) was added for 20 min at room temperature. 
After two final washes with FLEX buffer, the staining was 
visualized by adding diaminobenzidine (Dako UK Ltd.) 
for 10 min at room temperature. The slides were washed 
well in FLEX buffer and counterstained with EnVision 
FLEX HEMATOXILIN SM806 (K8008; Dako UK Ltd.) 
for 5 min, then washed once with FLEX buffer, then with 
water, and then dehydrated, cleared, and mounted with 
aqueous mounting media (LEICA AUTOSTAINER JUNG 
XL). Positive and negative controls were performed with 
each batch of slides.
Quantification of immunolabeling
A comparative quantification of immunolabeling in 
all tissues types was performed using Ki67 antibody. In 
each tumor section, the staining intensity (optical density) 
per unit surface area was measured with an automatic 
image analyzer (Motic Images Advanced version 3.2, 
Motic China Group Co., China) in 5 light microscopic 
fields per section, using the ×40 objective. Delimitation 
of surface area was carried out manually using the mouse 
of the image analyzer. For each positive immunostained 
section, one negative control section (the following in a 
series of consecutive sections) was also used, and the optic 
density of this control section was taken away from that of 
the stained section. From the average values obtained (by 
the automatic image analyzer) for each tumor, the means 
± SEM for each tumor (PBS and 14) were calculated. 
The number of sections examined was determined by 
successive approaches to obtain the minimum number 
required to reach the lowest SEM. The statistical 
significance between means of the tumors group’s samples 
was assessed by the Fisher exact test and the one-way 
ANOVA test at p≤0.05 (GraphPad PRISMA 5.0).
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